Skip to content
zameds

Cefprozil

Sold as Auroprozil, Lizorp, Cefprozil SPEC, Cefrprozil SPEC, Repocef

S4
Loading the molecular structure
C18H19N3O5S389.40 g/mol

(6R,7R)-7-[[(2R)-2-Amino-2-(4-hydroxyphenyl)acetyl]amino]-8-oxo-3-prop-1-enyl-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

Drag to rotate. Structure from PubChem CID 62977.

Background

Loading...
Loading Wikipedia summary

Registration

Applicants
3
Registrations
12
Schedule source
Consolidated Schedules 06 July 2026

Applicants and registrations

ApplicantBrandsDosagesRegistrationsScheduleLeaflets
Actor Pharma (Pty) Ltd - ApplicantCancelledAuroprozil250 mg, 500 mg410043, 410044S4None
Aurogen South Africa (Pty) LtdLizorp, Repocef125 mg/5 ml, 250 mg, 250 mg/5 ml, 500 mg410586, 410587, 430535, 430536, 430537, 430538S4None
Specpharm (Pty) LtdCefprozil SPEC, Cefrprozil SPEC125 mg /5 ml, 250, 250 mg/5 ml, 500 mg420233, 420234, 430475, 430476S4None

Variants

ProductStrength and formRegistrationStatusScheduleLeaflets
Auroprozil 250 MG

EACH TABLET CONTAINS CEFPROZIL MONOHYDRATE EQUIVALENT TO CEFPROZIL 250,0 mg

250 mg41004341/20.1.1/0043CancelledS4None
Auroprozil 500 MG

EACH TABLET CONTAINS CEFPROZIL MONOHYDRATE EQUIVALENT TO CEFPROZIL 500,0 mg

500 mg41004441/20.1.1/0044CancelledS4None
Lizorp 250 MG

EACH TABLET CONTAINS CEFPROZIL MONOHYDRATE EQUIVALENT TO CEFPROZIL 250,0 mg

250 mg41058641/20.1.1/0586RegisteredS4None
Lizorp 500 MG

EACH TABLET CONTAINS CEFPROZIL MONOHYDRATE EQUIVALENT TO CEFPROZIL 500,0 mg

500 mg41058741/20.1.1/0587RegisteredS4None
Cefprozil 250 SPEC

EACH TABLET CONTAINS CEFPROZIL 250,0 mg

25042023342/20.1.1/0233RegisteredS4None
Cefrprozil 500 MG SPEC

EACH TABLET CONTAINS CEFPROZIL 500,0 mg

500 mg42023442/20.1.1/0234RegisteredS4None
Cefprozil 125 MG /5 ML SPEC

EACH 5,0 ml SUSPENSION CONTAINS CEFPROZIL 125,0 mg

125 mg /5 ml43047543/20.1.1/0475RegisteredS4None
Cefprozil 250 mg/5 ML SPEC

EACH 5,0 ml SUSPENSION CONTAINS CEFPROZIL 250,0 mg

250 mg/5 ml43047643/20.1.1/0476RegisteredS4None
Lizorp suspension 125 mg/5 ML

EACH 5,0 ml SUSPENSION CONTAINS CEFPROZIL 125,0 mg

125 mg/5 mlSuspension43053543/20.1.1/0535RegisteredS4None
Lizorp suspension 250 mg/5 ML

EACH 5,0 ml SUSPENSION CONTAINS CEFPROZIL 250,0 mg

250 mg/5 mlSuspension43053643/20.1.1/0536RegisteredS4None
Repocef suspension 125 mg/5 ML

EACH 5,0 ml SUSPENSION CONTAINS CEFPROZIL 125,0 mg

125 mg/5 mlSuspension43053743/20.1.1/0537RegisteredS4None
Repocef suspension 250 mg/5 ML

EACH 5,0 ml SUSPENSION CONTAINS CEFPROZIL 250,0 mg

250 mg/5 mlSuspension43053843/20.1.1/0538RegisteredS4None

Regulatory status

Where S4 sits on the scale

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Cefprozil monohydrate equivalent to cefprozil

  • S4: Cefprozil

    Consolidated Schedules 06 July 2026, line 5735

Pharmacological class: Broad and medium spectrum antibiotics. (class 20.1.1)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

SAHPRA has not published a professional information or patient information leaflet for this product.

Research articles

Loading...
Loading PubMed articles